Image

Markers of Disease Progression and Gait Within the Parkinsonian Population

Markers of Disease Progression and Gait Within the Parkinsonian Population

Recruiting
30-80 years
All
Phase N/A

Overview

The aim of the project is to evaluate disease progression of patients with Parkinsonian syndrome of various severity through regular home-based gait parameters analysis.

We identified several steps in this project:

  1. Acquisition of gait data in 120 patients with Parkinsonism at different stages in hospital and ecological condition (during 10 days at home), in a repetitive manner:
  2. 30 Early PD patients, before 3 years of disease duration (MDS criteria, 2018)
  3. 30 PD patients with motor fluctuations (5 to 8 years of disease duration) (MDS criteria, 2018)
  4. 30 PD patients with FoG (10 years of disease duration) (MDS criteria, 2018)
  5. 30 patients with MSA (less than 5 years after the first symptom)
  6. Control groups will be composed by 30 healthy volunteers Correlation analysis with clinical measurements and biomarkers, namely blood biomarkers for neurodegeneration (4HN, NFLT …) and multimodal MRI repeated assessments (Iron overload, inflammation and degeneration) and genetic panel for common haplotypes involved in Parkinsonism.

Eligibility

Inclusion Criteria:

PD Patients:

  • Age: from 40 to 80 years
  • Absence of intercurrent pathology that may interfere with the purpose of the study (rheumatologic or orthopedic condition, cardiac, severe pulmonary disease that may limit the perimeter of walking)

Each group will be composed of:

  • 30 PD with a disease duration < 3 years
  • 30 PD with a disease duration between 5 to 8 years
  • 30 PD with a disease duration > 10 years MSA Patients
  • Age > 30 years old
  • < 5 years of disease duration
  • deemed by the physicians to be able to walk at 1 year

Healthy subjects

• Similar age and sex distribution

For all

  • Absence of intercurrent pathology that may interfere with the purpose of the study (rheumatologic or orthopedic condition, cardiac, severe pulmonary disease that may limit the perimeter of walking)
  • Absence of cognitive disorders (MoCA> 24/30 according to the MDS criteria)
  • Stable treatment for at least 2 weeks before inclusion
  • Ability to walk at least 100 meters
  • Have an affiliation to the social security or equivalent
  • Have signed an informed consent

Exclusion Criteria:

  • STN DBS for PD patients
  • Intraduodeno-jejunal levodopa infusion (duodopa)
  • Inability to walk without aid (walker or walking stick)

Study details
    Parkinson Disease

NCT04653688

University Hospital, Lille

9 March 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.